MX360787B - Metodos para reducir neurodegeneracion. - Google Patents
Metodos para reducir neurodegeneracion.Info
- Publication number
- MX360787B MX360787B MX2013014430A MX2013014430A MX360787B MX 360787 B MX360787 B MX 360787B MX 2013014430 A MX2013014430 A MX 2013014430A MX 2013014430 A MX2013014430 A MX 2013014430A MX 360787 B MX360787 B MX 360787B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- day
- neurodegeneration
- melatonin
- reducing
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 3
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 3
- 229960003987 melatonin Drugs 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/184—Hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/168—Steroids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La presente invención se refiere a una cantidad de melatonina que reduzca neurodegeneración para usarse para reducir neurodegeneración en un canino, en donde la melatonina es administrable en cantidades de 1ng/kg/día a 2 mg/kg/día. La cantidad de melatonina que reduzca neurodegeneración para usarse en donde la melatonina es administrable en una composición comestible, como por ejemplo una composición de alimento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161520332P | 2011-06-08 | 2011-06-08 | |
PCT/US2012/040658 WO2012170322A1 (en) | 2011-06-08 | 2012-06-04 | Methods for reducing neurodegeneration |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013014430A MX2013014430A (es) | 2014-01-20 |
MX360787B true MX360787B (es) | 2018-11-16 |
Family
ID=47296378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014430A MX360787B (es) | 2011-06-08 | 2012-06-04 | Metodos para reducir neurodegeneracion. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20140113949A1 (es) |
EP (1) | EP2717695B1 (es) |
JP (1) | JP6284473B2 (es) |
CN (1) | CN103582421A (es) |
AU (1) | AU2012268562B2 (es) |
BR (1) | BR112013031460A2 (es) |
CA (1) | CA2838461C (es) |
ES (1) | ES2605454T3 (es) |
MX (1) | MX360787B (es) |
RU (1) | RU2013158254A (es) |
WO (1) | WO2012170322A1 (es) |
ZA (1) | ZA201400115B (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1331313A (zh) * | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人p70核糖体S6激酶11.77和编码这种多肽的多核苷酸 |
AU2003230644A1 (en) * | 2002-03-14 | 2003-09-29 | Ercole L. Cavalieri | A unifying mechanism and methods to prevent cancer and neurodegenerative diseases |
AU2003259803B2 (en) * | 2002-08-12 | 2007-08-02 | The Regents Of The University Of Michigan | Diagnosis and treatment of tuberous sclerosis |
US7361681B2 (en) * | 2003-03-28 | 2008-04-22 | Sygnis Bioscience Gmbh & Co. Kg | Method of treating amytrophic lateral sclerosis using melatonin |
JP4993900B2 (ja) * | 2005-11-28 | 2012-08-08 | 国立大学法人 東京医科歯科大学 | 記憶障害抑制剤 |
ES2703571T3 (es) * | 2008-03-27 | 2019-03-11 | Nestec Sa | Métodos para aumentar la absorción de péptidos, peptidomiméticos y otros sustratos de proteína de transporte gastrointestinal |
-
2012
- 2012-06-04 AU AU2012268562A patent/AU2012268562B2/en not_active Ceased
- 2012-06-04 ES ES12796892.3T patent/ES2605454T3/es active Active
- 2012-06-04 CN CN201280027335.1A patent/CN103582421A/zh active Pending
- 2012-06-04 US US14/122,486 patent/US20140113949A1/en not_active Abandoned
- 2012-06-04 EP EP12796892.3A patent/EP2717695B1/en not_active Not-in-force
- 2012-06-04 RU RU2013158254/15A patent/RU2013158254A/ru unknown
- 2012-06-04 CA CA2838461A patent/CA2838461C/en not_active Expired - Fee Related
- 2012-06-04 JP JP2014514517A patent/JP6284473B2/ja not_active Expired - Fee Related
- 2012-06-04 WO PCT/US2012/040658 patent/WO2012170322A1/en active Application Filing
- 2012-06-04 BR BR112013031460A patent/BR112013031460A2/pt not_active Application Discontinuation
- 2012-06-04 MX MX2013014430A patent/MX360787B/es active IP Right Grant
-
2014
- 2014-01-07 ZA ZA2014/00115A patent/ZA201400115B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2014518899A (ja) | 2014-08-07 |
CA2838461A1 (en) | 2012-12-13 |
MX2013014430A (es) | 2014-01-20 |
AU2012268562B2 (en) | 2016-06-16 |
AU2012268562A1 (en) | 2013-12-19 |
ZA201400115B (en) | 2015-11-25 |
US20140113949A1 (en) | 2014-04-24 |
ES2605454T3 (es) | 2017-03-14 |
CN103582421A (zh) | 2014-02-12 |
JP6284473B2 (ja) | 2018-02-28 |
CA2838461C (en) | 2019-12-03 |
EP2717695B1 (en) | 2016-11-02 |
EP2717695A1 (en) | 2014-04-16 |
WO2012170322A1 (en) | 2012-12-13 |
EP2717695A4 (en) | 2014-06-18 |
BR112013031460A2 (pt) | 2016-08-16 |
RU2013158254A (ru) | 2015-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA110354C2 (uk) | Противірусні сполуки | |
MX341739B (es) | Compuestos de dihidroisoxazol parasiticidas. | |
UA115532C2 (uk) | Модулятори нуклеарного транспорту, що містять гідразид, і їхнє застосування | |
EP2415749A4 (en) | NEW SALVIANOLIC ACID CONNECTION L, PREPARATION METHOD AND USE | |
MX2014001180A (es) | Moduladores del transporte nuclear y usos de los mismos. | |
MX2014000341A (es) | Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades. | |
SG190785A1 (en) | Antiviral compounds | |
MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
MY155649A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
MX2013011591A (es) | Métodos y composiciones para tratar enfermedades neurodegenerativas. | |
MX2013011086A (es) | (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas. | |
GB2503852A (en) | Compounds for the treatment of neuropsychiatric disorders | |
PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
AU2016216741A1 (en) | Compositions and methods of use of an inappetance-controlling compound | |
IN2014CN04773A (es) | ||
IN2013DN02555A (es) | ||
MX2013004878A (es) | N-hetarilmetil pirazolilcarboxamidas. | |
MX2013013098A (es) | Metodos y composiciones para fomentar el crecimiento de la masa corporal magra. | |
IN2014DN03010A (es) | ||
MX353991B (es) | Agonista del receptor de 5-ht4 como agente procinetico. | |
IN2014KN00865A (es) | ||
MX2013014430A (es) | Metodos para reducir neurodegeneracion. | |
WO2010093615A3 (en) | Compounds, their syntheses, compositions, and methods to treat cancer | |
TW201613606A (en) | Therapeutic drug for chronic renal failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |